Immunovant Inc. (IMVT)
NASDAQ: IMVT · Biological Products, (No Diagnostic Substances) · Durham, NC
Our rating: Neutral
Call changed from Cautious to Neutral at $35.71, moderate conviction, November 10, 2026.
Breaks if: The Neutral call moves Cautious if the stock falls 35% or more from the current $35.71 within twelve months — a decline of that magnitude at this market cap would almost certainly reflect a pivotal-trial failure or a financing event signaling the runway is narrower than assumed, either of which would change the fundamental picture. It moves Positive if the stock clears and holds above $56 — roughly 57% above today — on the back of a material clinical or regulatory catalyst, at which point the market will have done the work of pricing a credible commercial inflection and the question shifts to durability rather than existence.
Key figures
| Market value | $6.6B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$509M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | n/a |
| Free cash flow yield | n/a |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −86.5% |
| Beta to the S&P 500 | 1.23 |
| Volatility, annualized | 55.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $-0.47 | n/a |
| June 30, 2026 | n/a | n/a | $-0.75 | n/a |
| March 31, 2026 | n/a | n/a | $-0.73 | −$95M |
| December 31, 2025 | n/a | n/a | $-0.61 | −$92M |
| September 30, 2025 | n/a | n/a | $-0.73 | −$103M |
| June 30, 2025 | n/a | n/a | $-0.71 | −$117M |
| March 31, 2025 | n/a | n/a | $-0.63 | −$111M |
| December 31, 2024 | n/a | n/a | $-0.76 | −$101M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 2%, Gemini 2%, Mistral 1%
- Free cash flow for the quarter is above zero: Claude 2%, Gemini 2%, Mistral 1%
14 ledger entries and 19 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.